Trump Administration Reaches Drug-Pricing Agreements With Nine Pharmaceutical Companies
Nine major drugmakers agreed to extend Most Favored Nation pricing to state Medicaid programs in exchange for tariff exemptions, alongside commitments for nearly $20 billion in United States manufacturing investment.